FY25 consensus $258.58M. Backs FY25 net product sales guidance in the range of $240M-$250M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals Reports Strong First Quarter 2025 Financial Results
- Aurinia Pharmaceuticals to Announce Q1 2025 Results
- Glass Lewis Supports Aurinia’s Proposals for 2025 AGM
- Aurinia Pharmaceuticals’ proposals receive recommendation from Glass Lewis
- ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting